Myungminwon
Myungminwon
Myungminwon is the highest concentration formulation of the Myungmin series and the one that presents the ✤greatest benefit for those suffering from dementia or Alzheimer's. It is a liquid based herbal supplement, produced under a carefully controlled enrichment process in an advanced FDA-compliant and registered manufacturing facility, ✤which enhances memory and improves concentration and cognitive functions. This set comes with 30 individual pouches - a one month's supply. It has the highest concentration of the active natural compounds that work to ✤fight beta amyloid plaque, stimulate neurogenesis, improve overall brain health while also aiding in enhancing memory and concentration. The liquid form allows for easier consumption for individuals who suffer from dysphagia or have difficulty with swallowing.
The disease that people today
fear
the most is
dementia
Myungmin
is the answer
Myungmin is the answer to fight back against dementia
1. Myungmin is a patented ✤treatment for dementia. Its safety and efficacy has been rigorously validated through numerous clinical trials.
2. Not getting grades consistent with the time spent studying? For ✤improving memory and concentration, look no further!
3. ✤Derived from wholly natural compounds, there is no concern for toxicity. Numerous individuals are currently taking Myungmin in their daily lives.
4. ✤No abnormalities observed in blood tests. No negative side effects such as nausea, indigestion, vomiting or diarrhea.
Fight Against Alzheimer's
First To Reach 3rd Phase Clinical Trial In Korea
Alzheimer treatment Myungmin has been tested in nonclinical and clinical studies in both animals and humans. The results ✤show increases in brain derived neurotrophics factor (BDNF) that promotes neurogenesis, substantial increases in the regeneration of brain cells in the hippocampus involved in learning and memory, and confirmed the significant improvements in cognitive ability in the studies conducted.
What is dementia?
❶
What is dementia?
Dementia is a set of symptoms related to brain function that shows as impairment in memory, linguistics abilities, temporal and spatial understanding, judgment and abstract thinking abilities which negatively impact one's ability to function and carry out everyday activities. It results in a tremendous strain in the daily life of the one afflicted and is detrimental to their relations with friends, family and caregivers around them. Alzheimer's is the most common cause of dementia, accounting for 60-70% of the cases of dementia worldwide.
A normal functioning brain
A brain atrophied by Alzheimer's
Types of dementia and their distribution
Source: Ministry of Health and Welfare, 2012
Cognitive disorder and behavioral disorder
(linguistic ability, visuospatial ability, task execution, calculating numbers, emotion and personality, short-term / long-term memory loss)
Source: Ministry of Health and Welfare, 2012
Source: Ministry of Health and Welfare, 2012
Dementia patients by age groups (from 65 years old or older)
Source: National Institute of Dementia, 2017
| Symptoms from the progression of dementia | |
| Memory Loss | Unable to remember any recent events |
| Language Impairment | Cannot recall words or names of people |
| Perception of Time | No sense of date or time |
| Situational Awareness | Constantly losing sense of direction, getting lost |
| Loss of Dexterity | Inability to use simple household devices and tools |
| Behavioral changes from progression of dementia | |
| Personality Change | Increase in aggression or stubbornness |
| Depression | Exhibiting depression and generally appearing agitated |
| Restlessness | Unable to sit still or exhibiting unintentional movement |
| Hallucinations | Hearing or seeing objects or people that are not really there |
| Delusions | Claiming personal property has been stolen by others |
| Indifference | General apathy and lack of interest in doing anything |
❷
Causes of dementia and drug treatments
1. Accumulation of beta-amyloid proteins in the brain that clump together
2. Inflammatory response to tau proteins, oxidation damage, vascular tissues, etc.
3. Other forms of nerve damage
2. Inflammatory response to tau proteins, oxidation damage, vascular tissues, etc.
3. Other forms of nerve damage
| Product Name | Drug Compound | Usage/Dosage | Active Mechanism | Side-Effects |
| Razadyne tablet (4, 8mg) Razadyne PR SR capsule (8, 16, 24mg) | Galantamine | 2 times/day for 4 weeks, 4 mg/dosage; 2 times/day after 4 weeks, 8 mg/dosage (maximum dosage of 24mg/day) | Acetylcholinesterase (AChE) inhibitor | Nausea, vomiting, diarrhea, stomachache, indigestion, loss of appetite, fatigue, dizziness, headache, drowsiness, weight loss |
| Exelon capsule (1.5, 3, 4.5, 6mg) | Rivastigmine | 2 times/day, 1.5mg/dosage; Titration up to 3, 6, 9, 12mg/day in 2-week intervals (maximum dosage of 12mg/day) | Acetylcholinesterase (AChE) inhibitor | Nausea, vomiting, diarrhea, stomachache, loss of appetite, dizziness, agitation |
| Aricept tablet (5, 10, 23mg) | Donepezil | 5mg/dosage once a day (for over 4 weeks); maintain a 5-10mg dosage per day | Acetylcholinesterase (AChE) inhibitor | Nausea, vomiting, muscle cramps, fatigue, vertigo, diarrhea |
| Namenda tablet (10mg) Namenda oral drops (10mg/g) | Memantine | 10mg/day; gradually increase dosage by 10mg/day in 1 week intervals; spread dosages of 20-30mg evenly over the course of the day (maximum dosage 60mg/day) | NDMA receptor antagonist | Dizziness, confusion, sleep disorder, agitation, fatigue, headache, constipation |
Source: Seoul National University, Bundang Hospital, Phamacology Department, 2005
Myungmin Pharmacological Effects in Animals
Preclinical Animal Studies
Results of Micro PET/CT imaging in mouse model of Alzheimer's type dementia, research in conjunction with the Korea Atomic Energy Research Institute
ChAT measurement results in CA1 and CA3 regions
PKC immunoreactive neuron activity measurements
Excerpts from the white paper showing glucose metabolism in the brain by Micro PET/CT imaging. Higher metabolism and the resulting brain activity is denoted by the deeper shades of red.
Myungmin Pharmacological Effects in Humans
❶
Clinical Human Studies
Results of IQ tests and P300 wave measurements done on students in the Department of Psychology, Korea University. Placebo and Myungmin were administred daily over the course of 6 weeks, tests were conducted before and after the 6 week trial.
Korean IQ equivalent test scores
(Placebo vs Myungmin)
(Placebo vs Myungmin)
P300a latency response time
(Placebo vs Myungmin)
(Placebo vs Myungmin)
P300b latency response time
(Placebo vs Myungmin)
(Placebo vs Myungmin)
❖ Study Results
The study on the students at Korea University between the placebo group and the Myungmin group ✤show an improvement in IQ scores and a shorter latency response time in P300a and P300b wave measurements among those in the Myungmin group.
**P300 wave is an event related potential elicited in the process of decision making. It is an endogenous potential, meaning it is one's reaction to a stimulus, not connected to physical attributes of a stimulus. P300a and P300b values are measured by EEG
Lower value is better, indicating quicker reaction times
Lower value is better, indicating quicker reaction times
❷
Selected as a Study from the Ministry of Health and Welfare
Research Period: June 2011 - May 2013
IRB of 4 Institutions: Seoul St Mary's Hospital, Seoul St. Vincent Hospital, Ilsan Hospital, Kyunghee University Medical Center
IRB of 4 Institutions: Seoul St Mary's Hospital, Seoul St. Vincent Hospital, Ilsan Hospital, Kyunghee University Medical Center
❖ Study Results
The 4 institutions conducted clinical trials on 125 patients and as with previous preclinical animal studies, clinical trials and research results, significant improvements were observed in the Myungmin test group. Clinically significant safety issues and side-effects were not observed.
Myungmin Safety Testing Standards
Testing Authority: Ewha Womans University College of Pharmacy
Tests were conducted on Myungmin to ensure purity of the individual compounds, including tests for the detection of heavy metals and high performance liquid chromatography to ensure no other foreign substances contaminate the product.
Test of the purity of the individual compounds
Test for presence of Heavy Metals
Test for presence of foreign contaminants
Test to determine long term stability of active compounds
Test to determine arsenic levels
Test to detect contaminant microbes
Myungmin Phase 3 (Final Phase) Clinical Trials
On September 27, 2018, Mediforum has received approval for the phase 3 clinical trial for dementia treatment, the first to reach such milestone in Korea.
As featured on YTN bizlife TV News Segment
Myungmin Patent
Mediforum has been issued a patent by the Korean Intellectual Property Office
Myungmin is an herbal medicine with proven safety and efficacy. It has an ✤excellent effect on the neurological functions of seni and improvements to the studying and concentration of students and professionals.
It has undergone exhaustive tests in safety, including tests for compound purity, arsenic and heavy metals, contaminants and foreign microbes. SOP and GMP policies are in place to ensure quality and consistency in production.
Patented formula includes the following ingredients: Lycium Chinense, Rehmannia Glutinosa, Dioscoreae Rhizoma, Cornus Officinalis, Poris Cocos, Alisma Canaliculatum and Paeonia Suffruticosa.
✤The lack of serious negative side-effects and impact on blood physiology and organs have been thoroughly investigated and documented with each and every clinical trial.
It has undergone exhaustive tests in safety, including tests for compound purity, arsenic and heavy metals, contaminants and foreign microbes. SOP and GMP policies are in place to ensure quality and consistency in production.
Patented formula includes the following ingredients: Lycium Chinense, Rehmannia Glutinosa, Dioscoreae Rhizoma, Cornus Officinalis, Poris Cocos, Alisma Canaliculatum and Paeonia Suffruticosa.
✤The lack of serious negative side-effects and impact on blood physiology and organs have been thoroughly investigated and documented with each and every clinical trial.
Patent Issued by KIPO
Fight Against Alzheimer's
Fighting Alzheimer's with lack of side-effects
As featured on YTN News TV Segment
Selected quotes from the video segment:
"In mouse model clinical trials, there was a 20% reduction in the amount of time to do a task in the Myungmin test group compared to the control group."
"There was a reduction of 50% in beta amyloid plaque among the group that took Myungmin."
"In addition, with the use of all natural traditional herbal compounds, there were no negative side-effects exhibited when taking Myungmin."
"It has been confirmed to be effective not only to elderly seniors, but has shown efficacy in younger healthy individuals and enhanced physical strength to those consuming it."
"There was a reduction of 50% in beta amyloid plaque among the group that took Myungmin."
"In addition, with the use of all natural traditional herbal compounds, there were no negative side-effects exhibited when taking Myungmin."
"It has been confirmed to be effective not only to elderly seniors, but has shown efficacy in younger healthy individuals and enhanced physical strength to those consuming it."
